Long-term treatment with bevacizumab for patients with metastatic colorectal cancer: case report.

Published

Journal Article

Bevacizumab is a monoclonal antibody to vascular endothelial growth factor that has demonstrated increased overall survival when added to standard chemotherapy regimens for metastatic colorectal cancer. Herein we report the cases of 2 patients who demonstrated prolonged survival times of almost 5 and 6 years, respectively, on various chemotherapy regimens that also included bevacizumab. Throughout most of their disease course, these patients maintained a good quality of life, with some adjustments of chemotherapy doses because of side effects. Bevacizumab was generally well tolerated in long-term use.

Full Text

Duke Authors

Cited Authors

  • Hurwitz, HI; Honeycutt, W; Haley, S; Favaro, J

Published Date

  • May 2006

Published In

Volume / Issue

  • 6 / 1

Start / End Page

  • 66 - 69

PubMed ID

  • 16796794

Pubmed Central ID

  • 16796794

International Standard Serial Number (ISSN)

  • 1533-0028

Digital Object Identifier (DOI)

  • 10.3816/CCC.2006.n.023

Language

  • eng

Conference Location

  • United States